REVIEW article

Front. Med.

Sec. Ophthalmology

Volume 12 - 2025 | doi: 10.3389/fmed.2025.1567159

Tackling visual impairment: Emerging avenues in ophthalmology

Provisionally accepted
Fang  LinFang Lin1Yuxing  SuYuxing Su1Chenxi  ZhaoChenxi Zhao1Farhana  AkterFarhana Akter2Shun  YaoShun Yao3Huang  ShengHuang Sheng4Shao  XiaodongShao Xiaodong3,5*Yizheng  YaoYizheng Yao6
  • 1Department of Ophthalmology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China
  • 2Graduate School of Arts and Sciences, Harvard University, Cambridge, Massachusetts, United States
  • 3Department of Neurosurgery, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China
  • 4Department of Ophthalmology, TongRen Municipal People’s Hospital, Tongren 554300, Guizhou Province, China., Guizhou, China
  • 5Sun Yat-sen University, Guangzhou, China
  • 6Department of Neurology and Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Soochow University, Suzhou 215025, Jiangsu Province, China., Suzhou, China

The final, formatted version of the article will be published soon.

Visual impairment, stemming from genetic, degenerative, and traumatic causes, affects millions globally. Recent advancements in ophthalmology present novel strategies for managing and potentially reversing these conditions. Here, we explore ten emerging avenuesincluding gene therapy, stem cell therapy, advanced imaging, novel therapeutics, nanotechnology, artificial intelligence (AI) and machine learning, teleophthalmology, optogenetics, bionics, and neuroophthalmologyall making strides to improve diagnosis, treatment, and vision restoration. Among these, gene therapy and stem cell therapy are revolutionizing the treatment of retinal degenerative diseases, while advanced imaging technologies enable early detection and personalized care.Therapeutic advancements like anti-vascular endothelial growth factor therapies and neuroprotective agents, along with nanotechnology, have improved clinical outcomes for multiple ocular conditions. AI, especially machine learning, is enhancing diagnostic accuracy, facilitating early detection, and personalized treatment strategies, particularly when integrated with advanced imaging technologies. Teleophthalmology, further strengthened by AI, is expanding access to care, particularly in underserved regions, whereas emerging technologies like optogenetics, bionics, and neuro-ophthalmology offer new hope for patients with severe vision impairment. In light of ongoing research, we summarize the current clinical landscape and the potential advantages of these innovations to revolutionize the management of visual impairments. Additionally, we address the challenges and limitations associated with these emerging avenues in ophthalmology, providing insights into their future trajectories in clinical practice. Continued advancements in these fields promise to reshape the landscape of ophthalmic care, ultimately improving the quality of life for individuals with visual impairments.

Keywords: Gene Therapy, Stem Cell Therapy, Nanotechnology, artificial intelligence, Teleophthalmology, optogenetics, Bionics, neuro-ophthalmology

Received: 26 Jan 2025; Accepted: 14 Apr 2025.

Copyright: © 2025 Lin, Su, Zhao, Akter, Yao, Sheng, Xiaodong and Yao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Shao Xiaodong, Sun Yat-sen University, Guangzhou, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Research integrity at Frontiers

94% of researchers rate our articles as excellent or good

Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


Find out more